Tau Pipeline Enabling Program V (T-PEP)
Forecasted
The Tau Pipeline Enabling Program V funds translational research to develop and advance therapies targeting tauopathies, led by the Alzheimer's Association.
Funder: Alzheimer's Association
Due Dates (Anticipated): May 2027 (Letter of Intent) | August 2027 (Full application)
Funding Amounts: Up to $750,000 total for up to 2 years; indirect costs capped at 10% for nonprofits, not allowed for for-profits.
Summary: Supports translational research to advance candidate therapies for tauopathies by funding milestone-driven projects focused on therapeutic development.
Key Information: This is a forecasted opportunity; all dates are projected and subject to change.
Description
The Tau Pipeline Enabling Program V (T-PEP) is designed to accelerate the translation of innovative academic discoveries into potential therapeutic candidates for tauopathies, including Alzheimer’s disease, progressive supranuclear palsy, and frontotemporal dementia. The program targets projects focused on development candidate selection, lead optimization, in vivo proof-of-concept, and IND-enabling studies for tau or tau-associated mechanisms. The aim is to bridge the gap between early-stage academic research and pharmaceutical development, enriching the pipeline of disease-modifying therapies for these neurodegenerative conditions.
